Tambotatug Pelitecan in Small-Cell Lung Cancer after Platinum-Based Therapy.

Tambotatug pelitecan significantly improves overall survival, progression-free survival, and objective response rates compared to topotecan in relapsed small-cell lung cancer patients after platinum therapy.

• Why it matters: This work addresses the need for more effective treatments for small-cell lung cancer that has progressed after initial platinum-based therapy, where current options are limited and often have high toxicity.
• What they did: A phase 3, multicenter, randomized trial assigned 451 patients to receive tambotatug pelitecan or topotecan, measuring overall survival, progression-free survival, objective response, and adverse events.
• The result: Patients treated with tambotatug pelitecan had a median overall survival of 13.3 months versus 9.4 months with topotecan, and a higher objective response rate of 59.1% versus 9.7%, with fewer severe adverse events.